Processa Pharmaceuticals’ (PCSA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $6.00 target price on the stock.

Processa Pharmaceuticals Stock Up 0.8 %

NASDAQ:PCSA opened at $1.03 on Thursday. The company has a market cap of $3.38 million, a P/E ratio of -0.30 and a beta of 0.66. The firm’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.48. Processa Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $17.40.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.